LIFE WITHOUT DISEASE is a pursuit that requires a continually expanding understanding of the immune system, and the ability to translate knowledge and discoveries developed in scientific research into technologies that improve life and health.
To best reach these goals, Technology Development focuses on:
The Technology Development team works closely with La Jolla Institute scientists to enable access to research tools and technologies essential for biomedical experimentation, and ensure intellectual property rights are protected to develop the appropriate incentives for commercial development before research results are disseminated for public benefit. The team regularly connects with industry to build strategic alliances and structure collaborations to support La Jolla Institute’s research and generate new discoveries.
The Technology Development team, in coordination with the Translational Research department, frequently engages with biotechnology, pharmaceutical and life sciences companies and boasts a number of partnerships, across many research areas, established to develop, transfer and translate LJI’s technologies for commercial applications. The collaborations range in depth and breadth depending on mutual interests. Whether with a U.S. subsidiary of a Japanese pharmaceutical dedicated to developing novel therapies for inflammation and autoimmunity to a small biotech company leveraging La Jolla Institute’s expertise to enable the company’s technology, the impact of La Jolla Institute’s study of the immune system extends well beyond the laboratory.
La Jolla Institute’s signature partnership with Kyowa Kirin is the longest academic-industry collaboration in the world. Throughout the 30+ year history, the partnership has provided a mutually beneficial scientific exchange of knowledge, expertise and resources to support biomedical research, and through this exchange, a number of La Jolla Institute’s technologies have entered into Kyowa Kirin’s R&D pipeline and human clinical studies.
A number of La Jolla Institute’s discoveries around Tumor Necrosis Factors have been partnered with major pharmaceutical companies for clinical development. Some of the partnerships have been announced by press release: CD40, LIGHT (Sanofi Aventis, Medgenics) and OX40L.
Outside of the Tumor Necrosis Factor family, several technologies are in early stage, pre-clinical and clinical development through partnerships with various pharmaceutical companies.
As an academic research organization, La Jolla Institute discoveries are often nascent and require cultivation. Determination, expertise, and experience are essential to drive devices, products, and therapies into the market place, and La Jolla Institute connects with seasoned entrepreneurs and investors to help lay the foundation for new companies and commercialize technologies.
